# Moderna Revenue Beats Despite Litigation Impact.

*biotech · news · 2026-05-01 · Benzinga*

## Key points

- Moderna's adjusted Q1 loss was $1.18 per share, far narrower than expected $3.81 loss.
- Revenue reached $389 million, significantly exceeding the consensus estimate of $227.97 million.
- International COVID vaccine sales increased due to long-term partnerships with government entities.
- Moderna began Phase 3 trials for its mRNA H5 pandemic flu vaccine candidate, mRNA-1018.

**Companies:** Moderna
**Countries:** United States, United Kingdom

[Read the full story on Benzinga](https://www.benzinga.com/markets/earnings/26/05/52217081/modernas-legal-hit-steals-spotlight-from-strong-sales)

---

Canonical: https://newsio.io/n/00c94403-7103-41be-b527-d6ef5e8548d1/moderna-revenue-beats-despite-litigation-impact-covid-19-vaccine-maker-reported
Summarized by Newsio from Benzinga. https://newsio.io/how-it-works